Table 2.
Comparisons of clinical characteristics, underlying diseases, and medications
| Characteristic | All patients | Without events | With events | p |
|---|---|---|---|---|
| Total cholesterol (mg/dL) | 187.5 ± 36.4 | 188.1 ± 36.0 | 190.6 ± 46.8 | 0.80 |
| Triglycerides (mg/dL) | 125 [IQR, 90–189] | 128 [IQR, 91–195] | 119.5 [IQR, 80.8–154] | 0.26 |
| HDL cholesterol (mg/dL) | 45.6 ± 13.1 | 45.6 ± 12.3 | 44.3 ± 16.2 | 0.70 |
| LDL cholesterol (mg/dL) | 111.6 ± 32.8 | 112.0 ± 32.2 | 121.1 ± 37.8 | 0.30 |
| Glucose (mg/dL) | 117.1 ± 45.8 | 117.7 ± 48.0 | 112.1 ± 23.0 | 0.64 |
| HbA1c (%) | 6.5 ± 1.9 | 6.4 ± 1.9 | 6.6 ± 1.8 | 0.65 |
| Serum creatinine (mg/dL) | 0.90 ± 0.36 | 0.90 ± 0.37 | 0.93 ± 0.22 | 0.77 |
| Hemoglobin (g/dL) | 13.3 ± 1.5 | 13.5 ± 1.5 | 12.3 ± 2.6 | 0.06 |
| Hypertension (%) | 43.1 | 43.0 | 43.8 | 0.95 |
| Hypercholesterolemia (%) | 68.2 | 68.4 | 62.5 | 0.89 |
| Diabetes mellitus (%) | 32.6 | 32.8 | 31.3 | 0.90 |
| Prior MI (%) | 62.5 | 59.4 | 87.5 | 0.03 |
| Prior heart failure (%) | 13.2 | 14.1 | 6.3 | 0.38 |
| Prior PCI (%) | 40.3 | 41.4 | 31.3 | 0.44 |
| Prior CABG (%) | 8.3 | 7.8 | 12.5 | 0.52 |
| Diuretics (%) | 17.6 | 19.0 | 6.3 | 0.21 |
| Statins (%) | 59.0 | 59.4 | 56.3 | 0.76 |
| ACEIs or ARBs (%) | 35.2 | 35.9 | 25.0 | 0.36 |
| β-blockers (%) | 41.5 | 41.3 | 43.8 | 0.85 |
| CCBs (%) | 23.9 | 23.8 | 25.0 | 0.92 |
Data represent mean ± standard deviation or frequency or median and interquartile range (IQR). Blood samples were obatained at fasting
HDL high-density lipoprotein, LDL low-density lipoprotein, Hb hemoglobin, MI myocardial infarction, PCI percutaneous coronary intervention, CABG coronary artery bypass grafting, BNP brain natriuretic peptide, ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker, CCB calcium channel blocker